TY - JOUR
T1 - Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers
T2 - The SWITCH ON trial protocol
AU - Tan, Ngoc H.
AU - Sablerolles, Roos S. G.
AU - Rietdijk, Wim J. R.
AU - Goorhuis, Abraham
AU - Postma, Douwe F.
AU - Visser, Leo G.
AU - Bogers, Susanne
AU - Geers, Daryl
AU - Zaeck, Luca M.
AU - Koopmans, Marion P. G.
AU - Dalm, Virgil A. S. H.
AU - Kootstra, Neeltje A.
AU - Huckriede, Anke L. W.
AU - van Baarle, Debbie
AU - Lafeber, Melvin
AU - GeurtsvanKessel, Corine H.
AU - de Vries, Rory D.
AU - van der Kuy, Paul-Hugo Marie
N1 - Funding Information: The trial is funded by Netherlands Organization for Health Research and Development ZonMw in the COVID-19 Vaccine program (project grant number: 10430072110001). Publisher Copyright: Copyright © 2022 Tan, Sablerolles, Rietdijk, Goorhuis, Postma, Visser, Bogers, Geers, Zaeck, Koopmans, Dalm, Kootstra, Huckriede, van Baarle, Lafeber, GeurtsvanKessel, de Vries and van der Kuy.
PY - 2022/11/29
Y1 - 2022/11/29
N2 - Vaccination against coronavirus disease 2019 (COVID-19) has contributed greatly to providing protection against severe disease, thereby reducing hospital admissions and deaths. Several studies have reported reduction in vaccine effectiveness over time against the Omicron sub-lineages. However, the willingness to receive regular booster doses in the general population is declining. To determine the need for repeated booster vaccinations in healthy individuals and to aid policymakers in future public health interventions for COVID-19, we aim to gain insight into the immunogenicity of the additional bivalent booster vaccination in a representative sample of the healthy Dutch population. The SWITCH ON study was initiated to investigate three main topics: i) immunogenicity of bivalent vaccines after priming with adenovirus- or mRNA-based vaccines, ii) immunological recall responses and reactivity with relevant variants after booster vaccination, and iii) the necessity of booster vaccinations for the healthy population in the future. Clinical trial registration: https://clinicaltrials.gov/, identifier NCT05471440.
AB - Vaccination against coronavirus disease 2019 (COVID-19) has contributed greatly to providing protection against severe disease, thereby reducing hospital admissions and deaths. Several studies have reported reduction in vaccine effectiveness over time against the Omicron sub-lineages. However, the willingness to receive regular booster doses in the general population is declining. To determine the need for repeated booster vaccinations in healthy individuals and to aid policymakers in future public health interventions for COVID-19, we aim to gain insight into the immunogenicity of the additional bivalent booster vaccination in a representative sample of the healthy Dutch population. The SWITCH ON study was initiated to investigate three main topics: i) immunogenicity of bivalent vaccines after priming with adenovirus- or mRNA-based vaccines, ii) immunological recall responses and reactivity with relevant variants after booster vaccination, and iii) the necessity of booster vaccinations for the healthy population in the future. Clinical trial registration: https://clinicaltrials.gov/, identifier NCT05471440.
KW - COVID-19
KW - adenovirus-based vaccine
KW - immune memory
KW - immune response
KW - mRNA vaccine
UR - http://www.scopus.com/inward/record.url?scp=85143892953&partnerID=8YFLogxK
U2 - https://doi.org/10.3389/fimmu.2022.1067749
DO - https://doi.org/10.3389/fimmu.2022.1067749
M3 - Article
C2 - 36524126
SN - 1664-3224
VL - 13
SP - 1067749
JO - Frontiers in immunology
JF - Frontiers in immunology
M1 - 1067749
ER -